Categories
Ailmemts & Remedies

Jaundice-A Royal Disease

Jaundice, icterus, hepatitis.” These three terms are interchanged by people to describe what they believe is a single common affliction, a disease that causes the skin and eyes to turn yellow. The word “jaundice” is actually a corrupted anglicised version of the French jaune coined in the 19th century by French physicians to describe what they thought was a single disease entity. Unaware of cause or cure, the discolouration was also called the morbus regius (the regal disease), with the belief that only the touch of a king could cure it.

Times have now changed and medicine has become evidence based. Tests can be done if a person becomes “jaundiced” to evaluate the “when, where and why”. Once the cause is removed, the disease will disappear.

The yellow colour is due to a pigment called bilirubin, normally produced in the spleen and liver when old red blood cells are broken down. The pigment is then metabolised in the liver and excreted. The level of bilirubin is usually 0.3 to 1.9mg/dl (milligrams per decilitre). The human eye can discern the yellow colour imparted by bilirubin when the level is three times or more than the normal 3mg/dl in the blood.

Infectious diseases can interfere with the ability of the liver cells to metabolise bilirubin. The most common infections are viral, commonly caused by the hepatitis group of viruses. There are several of these — some are transmitted through contaminated food or water, others through unprotected sex or unsterile injections.

Jaundice owing to viral hepatitis A is the commonest form of jaundice in young people. It is usually a mild self-limited disease that recovers spontaneously in one or two months. No specific treatment is required. Hepatitis B, C or E can be more severe, relapsing, fatal or chronic.

Out of this group, hepatitis A and B are preventable. Vaccination against hepatitis B is offered in a 3-dose schedule before the age of one year (it can be given later to anyone who missed it). Hepatitis A vaccine is given after the age of two years as a 2-dose schedule. Protection is almost 100 per cent.

Other infections caused by the herpes group of viruses, leptospirosis, cytomegalovirus, malaria or even severe bacterial sepsis can also cause jaundice. These diseases are not preventable by immunisation.

Jaundice is not always due to an infection. If for any reason the number of red blood cells destroyed is greater than normal, the liver is unable to cope with the overload of pigment and the person becomes jaundiced. This occurs in some hereditary blood disorders like thalassaemia, and sickle cell disease, or a hereditary metabolic defect like G6PD deficiency.

Sometimes, the liver cells themselves are defective and unable to cope with even the normal amount of bilirubin produced in the body. This occurs in certain inherited conditions like the Dubin-Johnson or the Gilbert syndrome. Several members of a family are affected, the jaundice is mild and fluctuating and it is not fatal.

Medications can be toxic to the liver and cause jaundice. Common examples are an overdose of paracetamol or even oestrogens. Alcohol is a direct toxin, poisonous to the liver cells. Consumption on a regular basis over many years can damage the liver and can result in jaundice.

Even when the bilirubin is adequately metabolised and produced in normal quantities, jaundice can occur, if the drainage ducts are blocked by stones, strictures and primary or secondary cancer deposits.

Sixty per cent of newborns can develop a “physiological” or normal self-limited jaundice. There is a rapid cell turnover in newborns and they produce bilirubin at a rate of 6 to 8 mg per kg per day, (more than twice the production rate in adults). The immature liver cells are initially unable to cope but the bilirubin production and level typically decline to the adult level within 10 to 14 days. Sometimes the jaundice is due to a mother-baby blood group incompatibility. The mother forms antibodies to the infant’s blood. This too is self limited and treatable.

The sudden appearance of jaundice in any age group should not be self diagnosed, ignored, treated with diet restrictions or herbs without a diagnosis. After consultations with a physician, appropriate blood and urine tests and, if necessary, scans or a laproscopy should be done to arrive at a diagnosis.

Eighty per cent of the jaundice in young adults is due to hepatitis A. As this disease is self-limited, quackery and miracle cures (like the touch of the king, amulets and bracelets) abound and appear successful.

Secondary jaundice recovers once the causative factor is removed. Abstaining from alcohol and discontinuing offending drugs may reverse jaundice. If a correctable obstruction is seen on scanning or a laparoscopy, surgical treatment provides relief.

The tragedy of jaundice is that ignorance and superstition stand in the way. Some treatable and curable forms of jaundice are not diagnosed or tackled till it is too late.

Disclaimer: This information is not meant to be a substitute for professional medical advise or help. It is always best to consult with a Physician about serious health concerns. This information is in no way intended to diagnose or prescribe remedies.This is purely for educational purpose.

Sources: The Telegraph (Kolkata, India)

Reblog this post [with Zemanta]
Categories
Herbs & Plants

Ji Gu Cao

[amazon_link asins=’B0081P5ARY,B01HGVYAKG,B00JO31N1Y,B0722KMVNV,B01N310R6X,B0195NDA9K,B00TNT667A,B01ACFF75U,B00KI0FGFG’ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’c650f2a9-7c49-11e7-b5c8-dd57792ea302′]

Botanical Name:Abrus fruticulosus Wall.ex Wight.et.Arn./ Abrus cantoniensis/ Abrus precatorius L.

Family:

Other Names:huang tou cao, da huang cao jia niu gan zi, hong mu ji caozhu yao caohuang se cao, xiao ye long ling cao
Tamil name: venkundri; Thai name: Maklam Phueak

Common Name: Chinese prayer bead grass

Local Name :Kacapiring ( Indonesia, Sunda), Ceplong saucer ( Java); Jempiring ( Acheh), Lutetium bruek, White king ( Acheh);

Description;
Kacapiring ( Gardenia) many looked after [by] people as ornamental plant or green fence having aroma fragrance interest. Kacapiring is including clump plant that is age annual and many having branch, close stick and also leaf. Kacapiring easy to grow any [by] place, either in cool area and also temperature. But, this plant more compatibly in mountain area or location that is height of more than 400 metre above permukaaan sea. Its(the tree trunk can reach height to shift 1-2 metre. Its(the interest is king sized, respects looking like white rose with [circle;coil] coronets and compiles forming one classy unities. Its(the leaf is in the form of oval, thick, lustrous and slippery at surface of its(the top leaf palm. Because fragrance of its(the interest, kacapiring has commercial value to be made perfume. Medium of breeding of this crop can be done by the way of cutting.

click to see the pictures

Medicinal Uses:

Properties(characteristics): sweet, slightly bitter, cool.

Actions & Indications:for acute viral hepatitis, stomach pain, breast cancer, tuberculosis of lymph glands, bruises and pain from injuries.

For acute hepatitis B

ji gu cao soup:

Ingredients: ji gu cao 38 g, bai hua she she cao 15 g, chi xiao dou 38 g, lean pork 110 g, sheng jiang   (raw ginger) 3 slices, hong zao 5 pieces, (cut open). Rinse all ingredients. Add water and make into soup.

Click to see:What is Rubia cordifolia and Rubia Root?Characters,Phytochemicals and Applications


Resources:

https://www.tcmassistant.com/herbs/ji-gu-cao.html
http://alternativehealing.org/ji_gu_cao.htm
http://traditional4fun.blogspot.com/2008_02_03_archive.html

Enhanced by Zemanta
Categories
Human Organ Transplantation

Liver Transplantation

[amazon_link asins=’1455702684,3319072080,0323528449,1118277384,0781720397,B009QOL4UQ,3798512566,8184487703,0323320163′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’6f1f2b71-7d87-11e7-bcd0-7568b2e27733′]

 

Introduction:Your liver helps fight infections and cleans your blood. It also helps digest food and stores energy for when you need it. You cannot live without a liver that works.

If your liver fails, your doctor may put you on a waiting list for a liver transplant. Doctors do liver transplants when other treatments cannot keep a damaged liver working.
Liver transplantation or hepatic transplantation is the replacement of a diseased liver with a healthy liver allograft. The most commonly used technique is orthotopic transplantation, in which the native liver is removed and the donor organ is placed in the same anatomic location as the original liver. Liver transplantation nowadays is a well accepted treatment option for end-stage liver disease and acute liver failure.

CLICK & SEE THE PICTURES

During a liver transplantation, the surgeon removes the diseased liver and replaces it with a healthy one. Most transplant livers come from a donor who has died. Sometimes a healthy person donates part of his or her liver for a specific patient. In this case the donor is called a living donor. The most common reason for transplantation in adults is cirrhosis. This is a disease in which healthy liver cells are killed and replaced with scar tissue. The most common reason in children is biliary atresia, a disease of the bile ducts.

People who have transplants must take drugs for the rest of their lives to keep their bodies from rejecting their new livers.

Liver transplantation is usually done when other medical treatment cannot keep a damaged liver functioning.

History:-
The first human liver transplant was performed in 1963 by a surgical team led by Dr. Thomas Starzl of Denver, Colorado, United States. Dr. Starzl performed several additional transplants over the next few years before the first short-term success was achieved in 1967 with the first one-year survival posttransplantation. Despite the development of viable surgical techniques, liver transplantation remained experimental through the 1970s, with one year patient survival in the vicinity of 25%. The introduction of cyclosporine by Sir Roy Calne markedly improved patient outcomes, and the 1980s saw recognition of liver transplantation as a standard clinical treatment for both adult and pediatric patients with appropriate indications. Liver transplantation is now performed at over one hundred centres in the USA, as well as numerous centres in Europe and elsewhere. One year patient survival is 80-85%, and outcomes continue to improve, although liver transplantation remains a formidable procedure with frequent complications. Unfortunately, the supply of liver allografts from non-living donors is far short of the number of potential recipients, a reality that has spurred the development of living donor liver transplantation.

Indications:-
Liver transplantation is potentially applicable to any acute or chronic condition resulting in irreversible liver dysfunction, provided that the recipient does not have other conditions that will preclude a successful transplant. Metastatic cancer outside liver, active drug or alcohol abuse and active septic infections are absolute contraindications. While infection with HIV was once considered an absolute contraindication, this has been changing recently. Advanced age and serious heart, pulmonary or other disease may also prevent transplantation (relative contraindications). Most liver transplants are performed for chronic liver diseases that lead to irreversible scarring of the liver, or cirrhosis of the liver.

Techniques
:-
Before transplantation liver support therapy might be indicated (bridging-to-transplantation). Artificial liver support like liver dialysis or bioartificial liver support concepts are currently under preclinical and clinical evaluation. Virtually all liver transplants are done in an orthotopic fashion, that is the native liver is removed and the new liver is placed in the same anatomic location. The transplant operation can be conceptualized as consisting of the hepatectomy (liver removal) phase, the anhepatic (no liver) phase, and the postimplantation phase. The operation is done through a large incision in the upper abdomen. The hepatectomy involves division of all ligamentous attachments to the liver, as well as the common bile duct, hepatic artery, hepatic vein and portal vein. Usually, the retrohepatic portion of the inferior vena cava is removed along with the liver, although an alternative technique preserves the recipient’s vena cava (“piggyback” technique).

The donor’s blood in the liver will be replaced by an ice-cold organ storage solution, such as UW (Viaspan) or HTK until the allograft liver is implanted. Implantation involves anastomoses (connections) of the inferior vena cava, portal vein, and hepatic artery. After blood flow is restored to the new liver, the biliary (bile duct) anastomosis is constructed, either to the recipient’s own bile duct or to the small intestine. The surgery usually takes between five and six hours, but may be longer or shorter due to the difficulty of the operation and the experience of the surgeon.

The large majority of liver transplants use the entire liver from a non-living donor for the transplant, particularly for adult recipients. A major advance in pediatric liver transplantation was the development of reduced size liver transplantation, in which a portion of an adult liver is used for an infant or small child. Further developments in this area included split liver transplantation, in which one liver is used for transplants for two recipients, and living donor liver transplantation, in which a portion of healthy person’s liver is removed and used as the allograft. Living donor liver transplantation for pediatric recipients involves removal of approximately 20% of the liver (Couinaud segments 2 and 3).

Immunosuppressive management:-
Like all other allografts, a liver transplant will be rejected by the recipient unless immunosuppressive drugs are used. The immunosuppressive regimens for all solid organ transplants are fairly similar, and a variety of agents are now available. Most liver transplant recipients receive corticosteroids plus a calcinuerin inhibitor such as tacrolimus or Cyclosporin plus a antimetabolite such as Mycophenolate Mofetil.

Liver transplantation is unique in that the risk of chronic rejection also decreases over time, although recipients need to take immunosuppresive medication for the rest of their lives. It is theorized that the liver may play a yet-unknown role in the maturation of certain cells pertaining to the immune system. There is at least one study by Dr. Starzl’s team at the University of Pittsburgh which consisted of bone marrow biopsies taken from such patients which demonstrate genotypic chimerism in the bone marrow of liver transplant recipients.

Results:-
About 80 to 90 percent of people survive liver transplantation. Survival rates have improved over the past several years because of drugs like cyclosporine and tacrolimus that suppress the immune system and keep it from attacking and damaging the new liver.

Prognosis is quite good. However those with certain illnesses may differ.  There is no exact model to predict survival rates however those with transplant have a 58% chance of surviving 15 years.

Living donor transplantation:-
Living donor liver transplantation (LDLT) has emerged in recent decades as a critical surgical option for patients with end stage liver disease, such as cirrhosis and/or hepatocellular carcinoma often attributable to one or more of the following: long-term alcohol abuse, long-term untreated Hepatitis C infection, long-term untreated Hepatitis B infection. The concept of LDLT is based on (1) the remarkable regenerative capacities of the human liver and (2) the widespread shortage of cadaveric livers for patients awaiting transplant. In LDLT, a piece of healthy liver is surgically removed from a living person and transplanted into a recipient, immediately after the recipient’s diseased liver has been entirely removed.

Historically, LDLT began as a means for parents of children with severe liver disease to donate a portion of their healthy liver to replace their child’s entire damaged liver. The first report of successful LDLT was by Dr. Silvano Raia at the Universidade de São Paulo (USP) Medical School in 1986. Surgeons eventually realized that adult-to-adult LDLT was also possible, and now the practice is common in a few reputable medical institutes. It is considered more technically demanding than even standard, cadaveric donor liver transplantation, and also poses the ethical problems underlying the indication of a major surgical operation (hepatectomy) on a healthy human being. In various case series the risk of complications in the donor is around 10%, and very occasionally a second operation is needed. Common problems are biliary fistula, gastric stasis and infections; they are more common after removal of the right lobe of the liver. Death after LDLT has been reported at 0% (Japan), 0.3% (USA) and <1% (Europe), with risks likely to improve further as surgeons gain more experience in this procedure.

In a typical adult recipient LDLT, 55% of the liver (the right lobe) is removed from a healthy living donor. The donor’s liver will regenerate to 100% function within 4-6 weeks and will reach full volumetric size with recapitulation of the normal structure soon thereafter. It may be possible to remove 70% to 75% of the liver from a healthy living donor without harm in most cases. The transplanted portion will reach full function and the appropriate size in the recipient as well, although it will take longer than for the donor.

For More Information:-

American Liver Foundation
75 Maiden Lane, Suite 603
New York, NY 10038
Phone: 1–800–GO–LIVER (465–4837)
Email: info@liverfoundation.org
Internet: www.liverfoundation.org

Hepatitis Foundation International (HFI)
504 Blick Drive
Silver Spring, MD 20904–2901
Phone: 1–800–891–0707 or 301–622–4200
Fax: 301–622–4702
Email: hepfi@hepfi.org
Internet: www.hepfi.org

United Network for Organ Sharing (UNOS)
P.O. Box 2484
Richmond, VA 23218
Phone: 1–888–894–6361 or 804–782–4800
Internet: www.unos.org

Additional Information on Liver Transplantation :-

The National Digestive Diseases Information Clearinghouse collects resource information on digestive diseases for National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Reference Collection. This database provides titles, abstracts, and availability information for health information and health education resources. The NIDDK Reference Collection is a service of the National Institutes of Health.

To provide you with the most up-to-date resources, information specialists at the clearinghouse created an automatic search of the NIDDK Reference Collection. To obtain this information, you may view the results of the automatic search on Liver Transplantation.

If you wish to perform your own search of the database, you may access and search the NIDDK Reference Collection database online.

National Digestive Diseases Information Clearinghouse
2 Information Way
Bethesda, MD 20892–3570
Phone: 1–800–891–5389
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: nddic@info.niddk.nih.gov
Internet: www.digestive.niddk.nih.gov

You may click to see->

Recent Developments in Transplantation Medicine

What I need to know about Liver Transplantation

Liver Transplantation at UCLA: One of the largest liver transplant centers in the world

You may click to see the external links:-
*Official organ sharing network of U.S.
*Official organ procurement center of the U.S.
*American Liver Foundation: Comprehensive information about Hepatitis C, Liver Transplant and other liver diseases, including links to chapters for finding local resources
*Management of HBV Infection in Liver Transplantation Patients
*Management of HCV Infection and Liver Transplantation
*Antiviral therapy of HCV in the cirrhotic and transplant candidate
*Living Donors Online
*Liver Transplantation Guide and Liver Transplant Surgery in India
*History of pediatric liver transplantation
*ABC Salutaris: Living Donor Liver Transplant
*Organ Donation Awareness and former potential donor blog
*All You Need to Know about Adult Living Donor Liver Transplantation
*Children’s Liver Disease Foundation
*A Liver Donor’s Blog

Resources:
http://www.nlm.nih.gov/medlineplus/livertransplantation.html
http://en.wikipedia.org/wiki/Liver_transplantation
http://digestive.niddk.nih.gov/ddiseases/pubs/livertransplant/

Reblog this post [with Zemanta]
Categories
Diagnonistic Test

Liver Biopsy

[amazon_link asins=’0702055484,1451182570,9386150263,1416026215′ template=’ProductCarousel’ store=’finmeacur-20′ marketplace=’US’ link_id=’10d5439b-481e-11e7-a279-8dc78a1dbcf4′]

In a liver biopsy (BYE-op-see), the physician examines a small piece of tissue from your liver for signs of damage or disease. A special needle is used to remove the tissue from the liver. The physician decides to do a liver biopsy after tests suggest that the liver does not work properly. For example, a blood test might show that your blood contains higher than normal levels of liver enzymes or too much iron or copper. An x ray could suggest that the liver is swollen. Looking at liver tissue itself is the best way to determine whether the liver is healthy or what is causing it to be damaged.

Preparation
Before scheduling your biopsy, the physician will take blood samples to make sure your blood clots properly. Be sure to mention any medications you take, especially those that affect blood clotting, like blood thinners. One week before the procedure, you will have to stop taking aspirin, ibuprofen, and anticoagulants.

You must not eat or drink anything for 8 hours before the biopsy, and you should plan to arrive at the hospital about an hour before the scheduled time of the procedure. Your physician will tell you whether to take your regular medications during the fasting period and may give you other special instructions.

 

Procedure
Liver biopsy is considered minor surgery, so it is done at the hospital. For the biopsy, you will lie on a hospital bed on your back with your right hand above your head. After marking the outline of your liver and injecting a local anesthetic to numb the area, the physician will make a small incision in your right side near your rib cage, then insert the biopsy needle and retrieve a sample of liver tissue. In some cases, the physician may use an ultrasound image of the liver to help guide the needle to a specific spot.

You will need to hold very still so that the physician does not nick the lung or gallbladder, which are close to the liver. The physician will ask you to hold your breath for 5 to 10 seconds while he or she puts the needle in your liver. You may feel pressure and a dull pain. The entire procedure takes about 20 minutes.

Two other methods of liver biopsy are also available. For a laparoscopic biopsy, the physician inserts a special tube called a laparoscope through an incision in the abdomen. The laparoscope sends images of the liver to a monitor. The physician watches the monitor and uses instruments in the laparoscope to remove tissue samples from one or more parts of the liver. Physicians use this type of biopsy when they need tissue samples from specific parts of the liver.

Transvenous biopsy involves inserting a tube called a catheter into a vein in the neck and guiding it to the liver. The physician puts a biopsy needle into the catheter and then into the liver. Physicians use this procedure when patients have blood-clotting problems or fluid in the abdomen.

Recovery
After the biopsy, the physician will put a bandage over the incision and have you lie on your right side, pressed against a towel, for 1 to 2 hours. The nurse will monitor your vital signs and level of pain.

You will need to arrange for someone to take you home from the hospital since you will not be allowed to drive after having the sedative. You must go directly home and remain in bed (except to use the bathroom) for 8 to 12 hours, depending on your physician’s instructions. Also, avoid exertion for the next week so that the incision and liver can heal. You can expect a little soreness at the incision site and possibly some pain in your right shoulder. This pain is caused by irritation of the diaphragm muscle (the pain usually radiates to the shoulder) and should disappear within a few hours or days. Your physician may recommend that you take Tylenol for pain, but you must not take aspirin or ibuprofen for the first week after surgery. These medicines decrease blood clotting, which is crucial for healing.

Like any surgery, liver biopsy does have some risks, such as puncture of the lung or gallbladder, infection, bleeding, and pain, but these complications are rare.

For More Information:
American Liver Foundation (ALF)
75 Maiden Lane, Suite 603
New York, NY 10038
Phone: 1–800–465–4837
1–888–443–7872
or 212–668–1000
Fax: 212–483–8179
Email: info@liverfoundation.org
Internet: www.liverfoundation.org

National Digestive Diseases Information Clearinghouse
2 Information Way
Bethesda, MD 20892–3570
Phone: 1–800–891–5389
TTY: 1–866–569–1162
Fax: 703–738–4929
Email: nddic@info.niddk.nih.gov
Internet: www.digestive.niddk.nih.gov

Sources:http://digestive.niddk.nih.gov/ddiseases/pubs/liverbiopsy/index.htm

Reblog this post [with Zemanta]
Categories
Ailmemts & Remedies

Nonalcoholic steatohepatitis or NASH

Definition:

Nonalcoholic steatohepatitis or NASH is a common, often “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.

NASH affects 2 to 5 percent of Americans. An additional 10 to 20 percent of Americans have fat in their liver, but no inflammation or liver damage, a condition called “fatty liver.” Although having fat in the liver is not normal, by itself it probably causes little harm or permanent damage. If fat is suspected based on blood test results or scans of the liver, this problem is called nonalcoholic fatty liver disease (NAFLD). If a liver biopsy is performed in this case, it will show that some people have NASH while others have simple fatty liver.

CLICK & SEE

Both NASH and NAFLD are becoming more common, possibly because of the greater number of Americans with obesity. In the past 10 years, the rate of obesity has doubled in adults and tripled in children. Obesity also contributes to diabetes and high blood cholesterol, which can further complicate the health of someone with NASH. Diabetes and high blood cholesterol are also becoming more common among Americans.

.Biliary system

Symptoms:
NASH is usually a silent disease with few or no symptoms. Patients generally feel well in the early stages and only begin to have symptoms—such as fatigue, weight loss, and weakness—once the disease is more advanced or cirrhosis develops. The progression of NASH can take years, even decades. The process can stop and, in some cases, reverse on its own without specific therapy. Or NASH can slowly worsen, causing scarring or “fibrosis” to appear and accumulate in the liver. As fibrosis worsens, cirrhosis develops; the liver becomes seriously scarred, hardened, and unable to function normally. Not every person with NASH develops cirrhosis, but once serious scarring or cirrhosis is present, few treatments can halt the progression. A person with cirrhosis experiences fluid retention, muscle wasting, bleeding from the intestines, and liver failure. Liver transplantation is the only treatment for advanced cirrhosis with liver failure, and transplantation is increasingly performed in people with NASH. NASH ranks as one of the major causes of cirrhosis in America, behind hepatitis C and alcoholic liver disease.
Liver Damage

.Liver Biopsy

Causes
Although NASH has become more common, its underlying cause is still not clear. It most often occurs in persons who are middle-aged and overweight or obese. Many patients with NASH have elevated blood lipids, such as cholesterol and triglycerides, and many have diabetes or pre-diabetes, but not every obese person or every patient with diabetes has NASH. Furthermore, some patients with NASH are not obese, do not have diabetes, and have normal blood cholesterol and lipids. NASH can occur without any apparent risk factor and can even occur in children. Thus, NASH is not simply obesity that affects the liver.

While the underlying reason for the liver injury that causes NASH is not known, several factors are possible candidates:

*insulin resistance

*release of toxic inflammatory proteins by fat cells (cytokines)

*oxidative stress (deterioration of cells) inside liver cells

Diagnosis
NASH is usually first suspected in a person who is found to have elevations in liver tests that are included in routine blood test panels, such as alanine aminotransferase (ALT) or aspartate aminotransferase (AST). When further evaluation shows no apparent reason for liver disease (such as medications, viral hepatitis, or excessive use of alcohol) and when x rays or imaging studies of the liver show fat, NASH is suspected. The only means of proving a diagnosis of NASH and separating it from simple fatty liver is a liver biopsy. For a liver biopsy, a needle is inserted through the skin to remove a small piece of the liver. NASH is diagnosed when examination of the tissue under the microscope shows fat along with inflammation and damage to liver cells. If there is fat without inflammation and damage, simple fatty liver or NAFLD is diagnosed. An important piece of information learned from the biopsy is whether scar tissue has developed in the liver. Currently, no blood tests or scans can reliably provide this information.
Treatment
It is important to stress that there are currently no specific therapies for NASH. The most important recommendations given to persons with this disease are to

*reduce their weight (if obese or overweight)
*follow a balanced and healthy diet
*increase physical activity
*avoid alcohol
*avoid unnecessary medications
These are standard recommendations, but they can make a difference. They are also helpful for other conditions, such as heart disease, diabetes, and high cholesterol.

A major attempt should be made to lower body weight into the healthy range. Weight loss can improve liver tests in patients with NASH and may reverse the disease to some extent. Research at present is focusing on how much weight loss improves the liver in patients with NASH and whether this improvement lasts over a period of time.

People with NASH often have other medical conditions, such as diabetes, high blood pressure, or elevated cholesterol. These conditions should be treated with medication and adequately controlled; having NASH or elevated liver enzymes should not lead people to avoid treating these other conditions.

Experimental approaches under evaluation in patients with NASH include antioxidants, such as vitamin E, selenium, and betaine. These medications act by reducing the oxidative stress that appears to increase inside the liver in patients with NASH. Whether these substances actually help treat the disease is not known, but the results of clinical trials should become available in the next few years.

Another experimental approach to treating NASH is the use of newer antidiabetic medications—even in persons without diabetes. Most patients with NASH have insulin resistance, meaning that the insulin normally present in the bloodstream is less effective for them in controlling blood glucose and fatty acids in the blood than it is for people who do not have NASH. The newer antidiabetic medications make the body more sensitive to insulin and may help reduce liver injury in patients with NASH. Studies of these medications—including metformin, rosiglitazone, and pioglitazone—are being sponsored by the National Institutes of Health and should answer the question of whether these medications are beneficial in NASH.

Click for alternative medication for NASH..……………….………(1)……(2)

Hope Through Research:-
What is most needed in the management of NASH is more research to better understand the liver injury found in this disease. When the pathways that lead to the injury are fully known, safe and effective means can be developed to reverse these pathways and help patients with NASH. Recent breakthroughs in mapping the human genome and uncovering the individual steps by which insulin and other hormones regulate blood glucose and fat could provide the necessary clues.

The National Institute of Diabetes and Digestive and Kidney Diseases funds the NASH Clinical Research Network, which comprises eight clinical centers located throughout the United States and a coordinating center at Johns Hopkins University. The NASH network researches the nature and underlying cause of NASH and conducts clinical studies on prevention and treatment. More information on the NASH Clinical Research Network and the locations of the clinical centers are available at www.nashcrn.com.

Important Points to Remember:-
Nonalcoholic steatohepatitis (NASH) is fat in the liver, with inflammation and damage.

NASH occurs in people who drink little or no alcohol and affects 2 to 5 percent of Americans, especially people who are middle-aged and overweight or obese.

*Nash can occur in children.
*People who have NASH may feel well and may not know that they have a liver disease.
*NASH can lead to cirrhosis, a condition in which the liver is permanently damaged and cannot work properly.
*Fatigue can occur at any stage of NASH.
*Weight loss and weakness may begin once the disease is advanced or cirrhosis is present.
*NASH may be suspected if blood tests show high levels of liver enzymes or if scans show fatty liver.
*NASH is diagnosed by examining a small piece of the liver taken through a needle, a procedure called biopsy.

People who have NASH should reduce their weight, eat a balanced diet, engage in physical activity, and avoid alcohol and unnecessary medications.

There are no specific therapies for NASH. Experimental therapies being studied include antioxidants and antidiabetes medications. (As NASH is common in uncontrolled diabetes. )

For More Information
American Liver Foundation (ALF)
75 Maiden Lane, Suite 603
New York, NY 10038–4810
Phone: 1–800–GO–LIVER (465–4837),
1–888–4HEP–USA (443–7872),
or 212–668–1000
Fax: 212–483–8179
Email: info@liverfoundation.org
Internet: www.liverfoundation.org

Disclaimer: This information is not meant to be a substitute for professional medical advise or help. It is always best to consult with a Physician about serious health concerns. This information is in no way intended to diagnose or prescribe remedies.This is purely for educational purpose

Sources:http://www.diabetesmonitor.com/b303.htm

Reblog this post [with Zemanta]
css.php